The use of the first-generation TKI drug, Imatinib, and the introduction of more potent the second-generation agents, Dasatinib, Nilotinib and Bosutinib TKIs [1], have improved the 10-year survival of patients newly diagnosed with CML, however none of these agents are active on patients harboring the BCR::ABL1T315I mutation [2]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.